Superluminal Medicines Secures $60M Series B to Advance Rare Obesity Drug Into Clinical Trials

Boston, MA, September 3, 2026 (PR Newswire) -- Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors. The company will use the funding to advance its lead selective MC4R agonist for rare genetic and hypothalamic obesity into a Phase 1 clinical trial expected to begin by the end of 2026. Proceeds will also support additional pipeline programs and expansion of Superluminal’s small-molecule GPCR discovery platform targeting endocrine and cardiometabolic diseases.

Read full article here.